Medigen Vaccine Biologics Corporation (6547)
TWSE
58.10
-0.70 (-1.19%)
Closed
Sep 14, 2026
Day's Range
56.5059.30
52 wk Range
33.5072.20
Financial Statements - 6547 - Medigen Vaccine Biologics Corporation
Revenue
613.17M▲ 1.2%
Net Income
-281.71M▼ 250.1%Net Margin -45.9%
EBITDA
-131.12M▼ 275.1%
Free Cash Flow
-100.86M▼ 1847.2%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 613.17M | 605.63M | 389.62M | 365.04M | 3.28B | 11.50M |
| Cost of Goods | 248.49M | 209.21M | 159.40M | 577.64M | 975.96M | 3.87M |
| Gross Profit | 364.67M | 396.42M | 230.22M | -212.60M | 2.30B | 7.63M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -265.69M | -145.66M | -1.21B | -1.53B | 963.73M | -763.88M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | -281.71M | -80.46M | -1.15B | -1.47B | 1.41B | -674.28M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -281.71M | -80.46M | -1.15B | -1.47B | 1.41B | -674.28M |
| EPS Basic | -0.86 | -0.24 | -3.53 | -4.56 | 4.42 | -2.425718 |
| EPS Diluted | -0.86 | -0.24 | -3.53 | -4.56 | 4.39 | -2.425718 |
| Basic Shares Outstanding | 328.74M | 328.66M | 328.56M | 323.37M | 214.95M | 278.27M |
| Diluted Shares Outstanding | 328.74M | 328.66M | 328.56M | 323.37M | 214.95M | 278.27M |
| Ebit | -272.91M | -61.57M | -1.12B | -1.44B | 1.41B | -657.86M |
| Ebitda | -131.12M | 74.86M | -991.09M | -1.31B | 1.52B | -535.60M |
| Net Income Continuous Operations | -281.71M | -80.46M | -1.15B | -1.47B | 1.41B | -674.28M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
